# TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

> **NCT05384756** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 2 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Alemtuzumab
- **PROCEDURE:** Hematopoietic Cell Transplantation
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT05384756
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-13
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2026-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05384756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05384756, "TMLI and Alemtuzumab for Treatment of Sickle Cell Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05384756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*